



Quantity: 100 µg

HRP-Mouse anti-Occludin

Catalog No. 33-1520

Lot No.

HRP-MONOCLONAL MOUSE ANTI-OCCLUDIN

FORM:

This HRP conjugated-monoclonal antibody is supplied as a 100 µl liquid aliquot at a concentration of 1 mg/ml in PBS, pH 7.4, containing 40% glycerol, 1% BSA, and 0.1% Proclin. The antibody is Protein A-purified from mouse ascites.

ANTIBODY SUMMARY:

Clone: OC-3F10

Isotype: Mouse IgG₁-κ.

Immunogen: GST fusion protein consisting of the C-terminal region of human occludin fused to GST.

SPECIFICITY:

This antibody reacts specifically with human, mouse, rat, and canine occludin.

REACTIVITY:

Reactivity of this antibody with the occludin protein has been confirmed by Western blotting and immunofluorescence. Tissues/lysates which showed positive reactivity: T84 cell line (human intestinal epithelium), MDCK cells (canine kidney), Caco-2 cells (human colon adenocarcinoma), and rat liver.

Unlike the Rabbit anti-Occludin polyclonal antibody (Cat. No. 71-1500), the mouse monoclonal antibody does not appear to detect the most highly phosphorylated form of the occludin protein when tested on Caco-2 cells. Therefore, the OC-3F10 antibody may have more limited utility than the polyclonal antibody for detecting the state of occludin phosphorylation under different conditions.

USAGE:

The concentrations listed below are good starting points; however, optimal concentrations should be determined by the investigator for each application.

ELISA: 0.1 - 1.0 µg/mL

Western Blotting: 0.1 - 1.0 µg/mL

(cont'd)

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

PI331520

(Rev 10/08) DCC-08-1089

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BACKGROUND

The establishment and maintenance of tight junctions is crucial to both the development and normal functioning of most organs.^(1,2) These junctions play dual roles in the physiological functions of both epithelial and endothelial cells.⁽¹⁾ Firstly, they function to create a barrier to the diffusion of solutes through the paracellular pathway.⁽¹⁾ Secondly, they function as a boundary between the apical and basolateral plasma membrane domains to create and maintain cell polarity.⁽¹⁾ Tight junctions (TJs) were first observed by electron microscopy over thirty years ago and were defined as a set of continuous, anastomosing intramembrane strands.⁽³⁾ Yet, information on the molecular organization, assembly, and functional regulation of these junctions has remained scarce. Over the past five years, some progress has been made in the identification of proteins which constitute TJs. The first TJ protein to be identified was the 220 kDa peripheral membrane protein ZO-1, localized at TJs in both epithelial and endothelial cells.^(4,5) This protein is also expressed in cells which lack TJs, such as fibroblasts; however, in these cell types, the ZO-1 protein is localized at adherens junctions.⁽⁶⁾ Subsequent studies revealed the existence of a ZO-1 homologue termed ZO-2. ZO-2 is also a peripheral membrane protein, but, unlike ZO-1, ZO-2 is found only at TJs.⁽⁷⁾ In addition to ZO-1 and ZO-2, other TJ-specific peripheral membrane proteins have been identified including cingulin, the 7H6 antigen, and symplekin.^(8,9,10) Another important discovery was the recent identification of the first transmembrane protein to be localized to tight junctions, termed occludin.^(11,12,13)

The 65 kDa occludin protein was first identified in chicken using monoclonal antibodies.^(11,12) The chicken occludin cDNA was subsequently cloned and sequenced, and the amino acid sequence revealed that the occludin protein is organized into five distinct domains: a short amino terminal cytoplasmic domain (domain A), two extracellular loops (domains B and D) separated by a short intracellular loop (domain C), and a long carboxy-terminal cytoplasmic tail (domain E).^(11,12) The C-terminal tail of occludin is required for both for its localization at tight junctions and for its direct interaction with the ZO-1 protein.⁽¹²⁾ One interesting feature of the occludin protein is that its amino acid sequence has not been highly conserved throughout evolution.⁽¹³⁾ This fact made isolating the mammalian homologues of chicken occludin a rather difficult task. Recently, however, the sequences of the full length cDNAs encoding occludin of rat-kangaroo, human, mouse, and dog were reported.⁽¹³⁾ At the amino acid level, the human, murine, and canine occludin proteins are highly homologous (~90% identity); however, the mammalian proteins exhibit a considerable degree of divergence from the rat-kangaroo and chicken proteins.⁽¹³⁾ Nevertheless, the overall structural features of the occludin protein are highly conserved in all the species examined.⁽¹³⁾ The recent identification and cloning of the mammalian occludin protein will undoubtedly facilitate the further study of TJ organization and function.

RELATED PRODUCTS:

	Cat. No.
• Mouse anti-Occludin	33-1500
• Rabbit anti-Occludin	71-1500
• Rabbit anti-ZO-1	61-7300
• Rabbit anti-ZO-2	71-1400
• Mouse anti-E-Cadherin	13-1700
• Rabbit anti- α -Catenin	71-1200
• Mouse anti- β -Catenin	13-8400
• Mouse anti- γ -Catenin	13-8500

STORAGE:

This antibody may be stored at 2-8°C

REFERENCES:

1. Anderson JM, et al. *Curr Opin Cell Biol* 5:772-778, 1993.
2. Gumbiner B. *Am J Physiol* 123:1631-1633, 1993.
3. Farquhar M, Palade G. *J Cell Biol* 17:375-409, 1963.
4. Stevenson BR, et al. *J Cell Biol* 103:755-766, 1986.
5. Anderson JM, et al. *J Cell Biol* 106:141-1149, 1988.
6. Itoh M, et al. *J Cell Biol* 115:1449-1462, 1993.
7. Gumbiner B, et al. *Proc Natl Acad Sci USA* 88:3460-3464, 1991.
8. Citi S, et al. *Nature* 33:272-276, 1988.
9. Zhong Y, et al. *J Cell Biol* 120:477-483, 1993.
10. Keon BH, et al. *J. Cell. Biol* 134:1003-1018, 1996.
11. Furuse M, et al. *J Cell Biol* 123:1777-1788, 1993.
12. Furuse M, et al. *J Cell Biol* 127:1617-1626, 1994.
13. Ando-Akatsuka Y, et al. *J Cell Biol* 133:43-47, 1996.

FOR RESEARCH USE ONLY

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

PI331520

(Rev 10/08) DCC-08-1089

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.